Eltrombopag (ELT)

DRUG2 trials

Sponsors

Novartis Pharmaceuticals, Fondazione Italiana Sindromi Mielodisplastiche-ETS

Conditions

Myelodysplastic NeoplasmMyelodysplastic SyndromeThrombocytopaenia

Phase 4

A Rollover Study to Provide Continued Treatment With Eltrombopag

CompletedNCT01957176

Novartis PharmaceuticalsThrombocytopaenia

Start: 2013-10-15End: 2022-02-23Updated: 2022-12-30

Unknown Phase

Observational Study on Eltrombopag in Hypocellular Myelodysplastic Neoplasms

Active, not recruitingNCT07825207

Fondazione Italiana Sindromi Mielodisplastiche-ETSMyelodysplastic Neoplasm, Myelodysplastic Syndrome

Start: 2026-05-01End: 2027-07-31Target: 100Updated: 2026-09-17